See it in Search
This page is a preview of the following resource. Continue onto eagle-i search using the button on the right to see the full record.
Randomized phase III trial of adjuvant therapy comparing chemotherapy alone (six cycles of docetaxel plus cyclophosphamide or four cycles of doxorubicin plus cyclophosphamide followed by weekly paclitaxel) to chemotherapy plus trastuzumab in women with node- positive or high-risk node-negative her2-low invasive breast cancer
eagle-i ID
http://hawaii.eagle-i.net/i/00000130-ddbf-8d09-9953-50a980000000
Resource Type
Properties
-
-
ClinicalTrials.gov url
-
http://www.clinicaltrials.gov/ct2/show/NCT01275677?term=NSABP+B-47&rank=1
-
-
Intervention
-
Cyclophosphamide
-
-
Intervention
-
Docetaxel
-
-
Intervention
-
Doxorubicin hydrochloride
-
-
Intervention
-
Paclitaxel
-
-
Intervention
-
Trastuzumab
-
-
Additional Topic(s)
-
Antineoplastic combined chemotherapy protocols
-
-
Resource Description
-
RATIONALE: It is not yet known whether combination chemotherapy is more effective with trastuzumab in treating breast cancer.
PURPOSE: This randomized phase III clinical trial is studying chemotherapy with or without trastuzumab after surgery to see how well they work in treating women with invasive breast cancer.
-
-
Contact
-
Berenberg, Jeffrey
-
-
PI
-
Berenberg, Jeffrey
-
-
Topic
-
breast cancer
-
-
Study Population
-
Females age 18 and older with a tumor that must be unilateral invasive adenocarcinoma of the breast on histologic examination.
-
-
Website(s)
-
http://www.cancer.gov/clinicaltrials/search/view?cdrid=692574&version=healthprofessional
-
-
Funded by
-
National Surgical Adjuvant Breast and Bowel Project
-
-
Phase
-
Phase 3 clinical trial
-
-
Performed by
-
Clinical Protocol & Data Management Shared Resource